← Back to all trials
Completed
NCT04572906
Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
Conditions: Peripheral Nerve Injuries
Sex: All
Ages: 12 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 51
Sponsor: Neuraptive Therapeutics Inc.
Location: UF Health - University of FL - Gainesville Gainesville Florida
Summary
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.
Eligibility Criteria
Inclusion Criteria:
* The subject is at least 12 years of age and not older than 80.
* The subject has sustained a confirmed (intra-op assessment) single transected peripheral nerve injury.
* The subject's nerve injury is classified as Sunderland's Fourth and Fifth Degree (Class III)
* The subject's nerve injury is amenable to minimal or acceptable tension, in direct, end-to-end repair.
* The surgical repair will occur within 48 hours of injury.
Exclusion Criteria:
* The subject has a PNI with a segmental loss (gap) that cannot be repaired with minimal or acceptable tension.
* Other treatments known to affect the growth and/or physiology of the neural and vascular system.
* The nerve injury has vascular damage that cannot be repaired to provide adequate perfusion of the injured site.
* The subject is pregnant and/or is breastfeeding.
* The subject has a significant medical comorbidity precluding immediate repair.
Source: ClinicalTrials.gov (NCT04572906). StuddyBuddy aggregates publicly available trial information.